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Abstract
Background: A cancer diagnosis can have a substantial impact on mental health and wellbeing. Depression and
anxiety may hinder cancer treatment and recovery, as well as quality of life and survival. We argue that more
research is needed to prevent and treat co-morbid depression and anxiety among people with cancer and that it
requires greater clinical priority. For background and to support our argument, we synthesise existing systematic
reviews relating to cancer and common mental disorders, focusing on depression and anxiety.
We searched several electronic databases for relevant reviews on cancer, depression and anxiety from 2012 to 2019.
Several areas are covered: factors that may contribute to the development of common mental disorders among
people with cancer; the prevalence of depression and anxiety; and potential care and treatment options. We also
make several recommendations for future research. Numerous individual, psychological, social and contextual
factors potentially contribute to the development of depression and anxiety among people with cancer, as well as
characteristics related to the cancer and treatment received. Compared to the general population, the prevalence
of depression and anxiety is often found to be higher among people with cancer, but estimates vary due to several
factors, such as the treatment setting, type of cancer and time since diagnosis. Overall, there are a lack of high-
quality studies into the mental health of people with cancer following treatment and among long-term survivors,
particularly for the less prevalent cancer types and younger people. Studies that focus on prevention are minimal
and research covering low- and middle-income populations is limited.
Conclusion: Research is urgently needed into the possible impacts of long-term and late effects of cancer
treatment on mental health and how these may be prevented, as increasing numbers of people live with and
beyond cancer.
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Background
A cancer diagnosis can have a wide-ranging impact on
mental health and the prevalence of depression and anx-
iety among people with cancer is high [1, 2]. Among
those with no previous psychiatric history, a diagnosis of
cancer is associated with heightened risk of common
mental disorders, which may adversely affect cancer
treatment and recovery, as well as quality of life and sur-
vival [3]. People who have previously used psychiatric
services may be particularly vulnerable and at greater
risk of mortality following a cancer diagnosis [4]. How-
ever, the mental health needs of people with cancer, with
or without a prior psychiatric history, are often given lit-
tle attention during and after cancer treatment, which is
primarily focused on monitoring physical health symp-
toms and side effects. Advances in the earlier detection
of cancer and improved cancer treatments means that
people are now living longer with cancer, presenting a
significant global challenge. The total number of people
who are alive within 5 years of a cancer diagnosis was
estimated to be 43.8 million in 2018 for 36 cancers
across 185 countries [5], and in the United States alone,
the number of cancer survivors is projected to rise
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exponentially from 15.5 million in 2016 to 26.1 million
in 2040 [6].
The main objective of this article is to argue that more
research is needed into the prevention, care and treat-
ment of co-morbid depression and anxiety among
people with cancer and highlight it as a growing clinical
and policy priority. For background and to support our
argument, we provide a current evidence review of sys-
tematic reviews relating to common mental disorders
amongst people living with and beyond cancer. We
cover the factors that may increase the risk of experien-
cing co-morbid depression and anxiety, epidemiology,
and potential care and treatment options.
We searched three key electronic databases: Medline,
PsycINFO and CINAHL (Cumulative Index to Nursing
and Allied Health Literature) for relevant reviews (favour-
ing those using systematic methods) using the following
search terms: (neoplasm OR carcinoma OR tumo*r OR
cancer) AND (depression OR anxiety) AND review. Only
English language articles were considered and searches
were limited to the years 2012 to 2017 and updated during
February 2019. These years were considered adequate to
capture the main themes relating to cancer and common
mental disorders in the current literature. The references
of highly relevant articles were scrutinised for additional
papers and a Google search for important grey literature
was also conducted. A minority of significant research ar-
ticles known to the authors were also consulted.
Main text
Factors influencing the development of depression and
anxiety among people with cancer
A variety of factors are likely to interact to influence the
development of depression and anxiety among people
with cancer (summarised in Fig. 1), but these are not well
understood [1], and require further research. Individual
Fig. 1 Factors that may contribute to depression and anxiety among people living with and beyond cancer
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risk factors that may increase the risk of depression, simi-
lar to the general population, include demographic factors,
such as age and gender, and social and economic factors
such as unemployment, fewer educational qualifications
and a lack of social support [7]. The development of de-
pression and anxiety among people with cancer is also
likely to depend on factors at the structural level, includ-
ing healthcare costs and access, as well as access to welfare
support, such as disability benefits, as cancer can have a
significant financial impact [8, 9]. Several psychological
factors are also important. A key factor is the presence of
pre-existing mental health problems and their severity.
Research has demonstrated that individuals who have
previously accessed mental health services before a cancer
diagnosis experience excess mortality due to certain
cancers, which may reflect late diagnosis, inadequate
treatment and a higher rate of adverse health behaviours
[4, 10]. Personality factors, such as neuroticism, and exist-
ing coping skills may also contribute [11]. The risk of
suicide among people with cancer is higher than the gen-
eral population for certain diagnoses that tend to have
poorer prognoses, such as mesothelioma and lung cancer,
especially in the first 6 months after diagnosis [12, 13].
Individuals who have previously engaged in suicidal be-
haviour are likely to be particularly vulnerable.
The individual psychological response to a cancer
diagnosis is also likely to be an important component.
The experience of being diagnosed, particularly if the
diagnosis has been delayed, can be a significant source
of distress and can impact on illness acceptance [14].
Feelings of hopelessness, loss of control and uncertainty
around survival and death can also have a detrimental
impact, particularly in patients with a poor prognosis.
Anxiety around a cancer diagnosis can also lead to sleep
disturbance, which may increase the risk of depression
[15]. The stigma surrounding both mental illness and
certain types of cancer, such as lung cancer, can lead to
feelings of guilt and shame, which could contribute to
the onset of depression. For example, the link between
smoking and lung cancer can lead to some patients
blaming themselves for their illness and experiencing
stigma if they have engaged in smoking [14].
A variety of factors related to the cancer and its treatment
are likely to impact on the development of depression and
anxiety, including the type of cancer, stage and prognosis.
Cancer treatments including immunotherapy and chemo-
therapy may induce depression through particular biological
mechanisms, such as inflammatory pathways, and some
medications used to treat chemotherapy-induced nausea
can reduce dopaminergic transmission, which is implicated
in the development of depressive symptoms [16]. The use of
steroids in cancer treatment can induce depression [17], and
androgen deprivation therapy in the treatment of prostate
cancer is also associated with increased risk [18]. The
physical symptoms of specific cancers can also contribute to
depression (e.g. incontinence and sexual dysfunction associ-
ated with prostate cancer) [19]. Iatrogenic distress is also
commonly reported amongst patients, which could increase
the risk of experiencing later problems with depression and
anxiety, including post-traumatic stress disorder [20]. This is
often related to a combination of poor communication, a
lack of consideration of psychological concerns and dis-
jointed care [14, 20].
Prevalence of depression and anxiety among people with
cancer
The prevalence of common mental disorders among
people with cancer varies widely in the published litera-
ture. The mean prevalence of depression using diagnos-
tic interviews is around 13% and using all assessment
methods it varies from approximately 4 to 49% [2, 21].
This wide variation is due to several factors including
the treatment setting, type of cancer included and
method used to screen for symptoms (e.g. interview by
trained psychiatrist or self-report instrument). The esti-
mated prevalence of depression was found to be 3% in
patients with lung cancer, compared to 31% in patients
with cancer of the digestive tract, when diagnostic inter-
views were used [21]. A meta-analyses of 15 studies
meeting a number of quality criteria, including the use
of diagnostic interviews, found that the estimated preva-
lence of depression varied across treatment settings (5 to
16% in outpatients, 4 to 14% in inpatients, 4 to 11% in
mixed outpatient and inpatient samples, and 7 to 49% in
palliative care) [2]. There is no universal standardised tool
which is recommended for depression screening in patients
with cancer and the method used is likely to differ depend-
ing on the treatment setting. A meta-analysis of screening
and case finding tools for depression in cancer settings iden-
tified 63 studies that used 19 different screening tools for
depression [22]. Common screening methods for depression
include semi-structured diagnostic interviews, the Hospital
Anxiety and Depression Scale - depression subscale (HADS-
D) and Center for Epidemiologic Studies Depression Scale
(CESD), which are designed to measure the severity of
depressive symptoms.
An important aspect that needs to be considered is the
timing of increased psychiatric risk. Studies demonstrate
that depression tends to be highest during the acute
phase and decreases following treatment, but again this
likely differs depending on the type of cancer and prog-
nosis [21]. Using diagnostic interviews, the prevalence of
depression during treatment was found to be 14%, 9% in
the first year after diagnosis and 8% a year or more after
treatment in a meta-analysis of 211 studies [21]. Of the
238 cohorts included, around 30% included only breast
cancer patients and there is a need for research includ-
ing rarer types of cancer.
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As well as the type of cancer, the type of mental health
outcome considered is also important and fewer studies
have examined anxiety. A systematic review and meta-
analysis study focusing on patients with ovarian cancer
found that anxiety tended to be higher following treatment
(27%) and during treatment (26%), and was lowest pre-
treatment (19%) [23]. The heightened anxiety observed
post-treatment may be due to reduced clinical consultations
and support following treatment, potential transfer to a pal-
liative setting, and fear of recurrence. Fear of recurrence is
one of the most commonly reported issues and an import-
ant area of unmet need for cancer survivors [24]. A lack of
outward physical symptoms in ovarian cancer also means
that self-monitoring is difficult [23]. In the same study of
ovarian cancer patients, depression was highest before treat-
ment (25%) and during treatment (23%), and reduced fol-
lowing treatment (13%). This is in the context of a lifetime
prevalence for clinical depression and anxiety of around 10
and 8%, respectively, amongst women in the UK [23, 25].
A similar systematic review of depression and anxiety
among patients with prostate cancer found that anxiety
tended to be highest pre-treatment (27%) and lowered
during treatment (15%) and post-treatment (18%) [26].
Rates of depression were relatively similar following
treatment (18%), during treatment (15%) and pre-
treatment (17%), with the 95% confidence intervals for
these estimates largely overlapping. For reference, the
prevalence of clinical depression and anxiety in men
aged over 65 years is less than 9 and 6%, respectively
[26]. A systematic review on the prevalence of psycho-
logical distress among testicular cancer survivors dem-
onstrated that around one in five experienced clinically
significant anxiety, compared to one in eight among
general population controls, with fear of recurrence
again being one of the key issues reported [27]. How-
ever, depression was no more prevalent amongst those
surviving testicular cancer compared to the general
population. In Scotland, the prevalence of depression
was found to be highest in patients with lung cancer
(13%), followed by gynaecological cancer (11%), breast
cancer (9%), colorectal cancer (7%), and genitourinary
cancer (6%) [28]. The authors found depression to be
more likely among younger and more socially disadvan-
taged individuals. In addition, 73% of the patients with
depression were not receiving treatment for their men-
tal health. Further research is needed to ascertain the
factors which contribute to the uptake and efficacy of
treatment for depression. This study also only consid-
ered people with cancer who had attended specialist
cancer clinics within a defined time period, which likely
excluded people who were diagnosed many years ago.
The longer-term psychological impact of cancer has
received comparatively little research. The few studies in
this area have mainly focused on women with breast
cancer and demonstrate that depressive symptoms can
persist for over 5 years after diagnosis, though the preva-
lence of anxiety was not elevated compared to the
general population [29]. A systematic review of the
prevalence of depression and anxiety among long-term
cancer survivors, including all types, found that anxiety
was more prevalent among cancer survivors, compared
to healthy controls [30]. Few studies have focused specif-
ically on younger cancer survivors and more research is
needed in this area. A representative study of young
adult cancer survivors aged 15 to 39 years in the United
States demonstrated that moderate (23% vs 17%) and se-
vere (8% vs 3%) mental distress were significantly higher
in those living with cancer for at least 5 years after diag-
nosis, compared to controls [31]. 75 and 52% of people
with cancer with moderate and severe distress, respect-
ively, had not talked to a mental health professional,
with the cost of treatment a potential barrier. Limita-
tions of this study included the focus on self-reported
mental distress and not clinical depression or anxiety, as
well as the relatively small sample size.
Many studies in this area have a poor response rate,
lack representativeness, are based on a small sample of
patients (often with the most common types of cancer),
which often exclude those with cognitive impairment
and patients who are too physically or mentally unwell
to take part [32]. Future studies would benefit from
using administrative health data [33], for example, link-
ing together cancer registries, inpatient and outpatient
records and prescribing data. There are also a lack of
studies covering populations from low- and middle-
income countries [34]. The estimated prevalence of co-
morbid common mental disorders is likely to vary de-
pending on the country studied, due to factors such as
the health and welfare system. These factors may influ-
ence mental health inequalities among people with can-
cer, which has received little research focus. In a
Scottish study, depression was found to be higher in the
least advantaged groups (19%), compared to the most
advantaged (10%) [35]. Cancer and comorbid anxiety
was also unequally distributed; in the least advantaged
groups around 12% had both conditions, compared to
7% among the most advantaged [35]. Further research is
needed in this area to quantify, monitor and prevent in-
equalities among people with cancer.
It should also be highlighted that the psychological im-
pact of cancer may not always be negative and many
people will not experience problems with depression and
anxiety. Experiencing temporary distress related to a can-
cer diagnosis may lead to positive psychological changes
in the long-term whereby individuals feel a greater appre-
ciation of life and are able to re-evaluate their priorities
[36]. The factors that protect against the development of
common mental disorders and contribute to positive
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mental health among people living with and beyond can-
cer merits further research.
Treatment and management of depression and anxiety
among people with cancer
To effectively manage and treat depression and anxiety
among people with cancer, symptoms must first be identi-
fied. However, several social and clinical barriers have
been reported. A key issue is the lack of physician time for
assessing symptoms. There can also be a normalisation of
distress and attribution of the somatic symptoms of
depression and anxiety to the cancer. Patients may not
disclose psychiatric symptoms because of the stigma sur-
rounding mental health conditions [37]. Screening for de-
pression and anxiety among patients with cancer is also
only of value if it leads to effective treatment and support
that is able to improve patient outcomes. Patients may be
more reluctant to discuss their mental health needs if they
perceive a lack of effective treatment options.
The existing evidence for treating anxiety and depression
among patients with cancer is limited and of varying quality
[38]. Studies with small sample sizes are common; this miti-
gates against the detection of meaningful changes in patient
outcomes and these studies often suffer from a high rate of
attrition, which likely reflects the high symptom burden
and reduced survival in this patient population [39]. Sys-
tematic reviews demonstrate there is a preponderance of
studies from the United States, which include a high num-
ber of studies focusing on female patients with breast
cancer [40]. However, these studies demonstrate that psy-
chotherapy, psychoeducation and relaxation training may
have small to medium short-term effects on relieving emo-
tional distress and reducing symptoms of anxiety and
depression, as well as improving health-related quality of
life. The evidence for pharmacological treatment of depres-
sion with antidepressants is mixed - there are very few
studies in this area and those that exist are of low quality
[41]. There is also concern around potential side effects of
antidepressants and drug interactions that may affect the
efficacy of cancer treatments [42].
A systematic review and meta-analysis focusing on
cognitive behavioural therapy (CBT) found that it may
be effective in reducing depression and anxiety and im-
proving quality of life in patients with cancer in the
short-term, but potential long-term effects were only
sustained for quality of life [43]. However, in this meta-
analysis the included participants were primarily women
with breast cancer and there are a lack of studies cover-
ing other cancer types. It is likely that collaborative care
interventions which involve partnership between psych-
iatry, clinical psychology and primary care, overseen by a
care manager are likely to be most effective in the man-
agement and treatment of depression amongst people
with cancer [44]. Treatment should be based on patient
preference and also take into account potential adverse
side effects [44]. In a UK-based study it was found that
only a third of patients with cancer and related psycho-
logical or emotional distress were willing to be referred
for support [45]. Qualitative studies also demonstrate
that patients often do not want to discuss their feelings
with nurses during cancer treatment [46]. However, pa-
tients valued having the option to talk about their emo-
tions, but they preferred to choose with whom and
when. There is therefore a need for further research into
some of the barriers to obtaining mental health support
among those affected by cancer and experiencing dis-
tress to prevent future problems.
The self-management of psychological distress among
people with cancer may be beneficial and could help pre-
vent distress becoming clinical depression or anxiety. Self-
management can be defined as: “The individual’s ability to
manage the symptoms, treatment, physical and psychosocial
consequences and lifestyle changes inherent in living with a
chronic condition. Efficacious self-management encompasses
the ability to monitor one’s condition and to affect the cogni-
tive, behavioural and emotional responses necessary to
maintain a satisfactory quality of life. Thus, a dynamic and
continuous process of self-regulation is established.” [47].
Studies on self-management, cancer and psychological dis-
tress have focused on the treatment phase, with fewer
investigating interventions following treatment or at the
end of life [48]. There is evidence to suggest that self-
management of psychological distress in cancer can help to
empower patients and families to care for themselves in a
way which is preferable for them. Self-management inter-
ventions that have shown promise include education, moni-
toring, teaching and counselling to help patients manage
the short- and long-term physical and psychosocial effects
of cancer [48]. However, a recent systematic review exam-
ining the impact of self-management interventions on
outcomes including quality of life, self-efficacy and symp-
tom management (such as psychological distress) amongst
cancer survivors demonstrated a lack of evidence to sup-
port any specific intervention and found that the six
included interventions lacked sustainability, bringing into
question their long-term effectiveness and value for money
[49]. Again, the included studies were dominated by
women with breast cancer, with only two covering other
cancers.
Effective treatment and management strategies may
also differ according to the demographic group affected.
In a report by CLIC (Cancer and Leukaemia in Child-
hood) Sargent which surveyed 146 young people with
cancer, keeping in touch with friends and family, talking
to others with similar experiences and access to the
internet in hospital were reported to help maintain men-
tal health during cancer treatment [50]. Of the young
people who mentioned they would find it helpful to talk
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to other people with similar experiences, 60% said they
would prefer to do this online. Young people also
reported that the available services were not tailored to
deal with those aged under 18 or the emotional impact
of cancer. In addition, those who accessed services men-
tioned that there is a lack of suitable long-term emo-
tional support. Just over 40% of the young people who
took part did not access support for their mental health
needs.
It is clear that a more personalised approach to support-
ing the psychological health of people with cancer is
needed [51]. Some people may not want or require sup-
port or treatment, others will be able to self-manage, and
some may have more complex needs that require more
intensive follow-up and support. At diagnosis, the psycho-
logical health of patients should be considered alongside
their physical health and sources of support offered. Needs
and symptoms may also change over time. Evaluation of
more recent personalised approaches to follow-up care
that have been adopted in several areas including England
and Northern Ireland [51] are needed to understand the
role they may have in preventing longer term depression
and anxiety amongst cancer survivors.
A key barrier affecting research progress in this area is
funding [52]. In the UK, money spent on research into
the biology of cancer was more than five times than that
spent on ‘Cancer Control, Survivorship and Outcomes’
during 2017/18 [53]. Research into the mental health
and wellbeing of people living with and beyond cancer
is likely to only be a small part of this. Research is ur-
gently needed in this area as more people survive cancer
and for some cancers, such as multiple myeloma and
colorectal cancer, risk is increasing in younger cohorts
[54]. The long-term (those that begin during treatment
and continue afterwards) and late effects of cancer treat-
ment (those that begin after treatment is completed),
such as secondary cancers, infertility, chronic pain and
insomnia, are likely to affect the mental wellbeing of
cancer survivors, potentially contributing to depression
and anxiety [6]. The National Cancer Research Institute
(NCRI) in the UK have also recently highlighted re-
search into the short-term and long-term psychological
impacts of cancer and its treatment as a key priority, fol-
lowing surveys of over 3500 patients, carers, and health
and social care professionals [55].
Conclusion
The mental health of people living with and beyond cancer
in its various types and stages is an important and growing
research and clinical priority. Compared to the general
population, the prevalence of anxiety and depression is often
higher among people with cancer, but estimates vary due to
a number of factors, such as the type and stage of cancer.
Patients often do not obtain psychological support or
treatment. This is likely due to several factors, including lack
of awareness and identification of psychiatric symptoms, an
absence of support available or offered, lack of evidence
around effective treatments, stigma, and patient preference.
In particular, we highlight the lack of high-quality research
into the mental health of long-term cancer survivors, the po-
tential impact of long-term and late effects of cancer treat-
ment, and the few studies focused on prevention. Further
research that includes the less common types of cancer is
required, as well as the inclusion of younger people and
populations from low- and middle-income countries. Given
the increasing numbers of people living with and beyond
cancer, this research is of timely importance.
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